Brief: HilleVax Announces Positive Immunogenicity Results For Run-In Cohort Of NEST-IN1 Phase 2b Clinical Trial Of HIL-214 Norovirus Vaccine Candidate
05/12/2022 11:40
Dec 5 (Reuters) - Hillevax Inc HLVX.O :
* HILLEVAX ANNOUNCES POSITIVE IMMUNOGENICITY RESULTS FOR
RUN-IN
COHORT OF NEST-IN1 PHASE 2B CLINICAL TRIAL OF HIL-214 NOROVIRUS
VACCINE CANDIDATE
* HILLEVAX INC - NOW LOOK FORWARD TO FULL NEST-IN1 TOPLINE
SAFETY
AND EFFICACY DATA WHICH REMAIN ON-TRACK FOR SECOND HALF OF 2023
* HILLEVAX INC - STUDY IS PLANNED TO ENROLL 3,000 SUBJECTS
WHO
WILL BE RANDOMIZED 1:1 TO RECEIVE A TWO-DOSE REGIMEN OF EITHER
HIL-214 OR PLACEBO
Source text for Eikon: ID:nGNX6VsNVY
Further company coverage: HLVX.O
Recent news on HilleVax
See all newsBrief: XOMA Royalty Announces Closing Of Tender Offer For HilleVax
Brief: Hillevax Enters Into A Definitive Agreement To Be Acquired By Xoma Royalty For $1.95 In Cash Per Share Plus A Contingent Value Right
U.S. STOCKS ON THE MOVE-US energy sector, Oshkosh, Meta
U.S. STOCKS ON THE MOVE-Zumiez, BTC Digital, WesBanco
U.S. STOCKS ON THE MOVE-Petco Health, Smith & Wesson, Victoria's Secret